6XC7 image
Deposition Date 2020-06-08
Release Date 2020-07-08
Last Version Date 2024-10-23
Entry Detail
PDB ID:
6XC7
Title:
Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.3 and CR3022
Biological Source:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.88 Å
R-Value Free:
0.25
R-Value Work:
0.21
R-Value Observed:
0.22
Space Group:
P 41 21 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Spike protein S1
Gene (Uniprot):S
Chain IDs:A
Chain Length:231
Number of Molecules:1
Biological Source:Severe acute respiratory syndrome coronavirus 2
Polymer Type:polypeptide(L)
Molecule:CC12.3 heavy chain
Chain IDs:D (auth: C)
Chain Length:220
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:CC12.3 light chain
Chain IDs:E (auth: D)
Chain Length:215
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:CR3022 heavy chain
Chain IDs:B (auth: H)
Chain Length:222
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:CR3022 light chain
Chain IDs:C (auth: L)
Chain Length:221
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation

Abstact

Molecular understanding of neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could accelerate vaccine design and drug discovery. We analyzed 294 anti-SARS-CoV-2 antibodies and found that immunoglobulin G heavy-chain variable region 3-53 (IGHV3-53) is the most frequently used IGHV gene for targeting the receptor-binding domain (RBD) of the spike protein. Co-crystal structures of two IGHV3-53-neutralizing antibodies with RBD, with or without Fab CR3022, at 2.33- to 3.20-angstrom resolution revealed that the germline-encoded residues dominate recognition of the angiotensin I converting enzyme 2 (ACE2)-binding site. This binding mode limits the IGHV3-53 antibodies to short complementarity-determining region H3 loops but accommodates light-chain diversity. These IGHV3-53 antibodies show minimal affinity maturation and high potency, which is promising for vaccine design. Knowledge of these structural motifs and binding mode should facilitate the design of antigens that elicit this type of neutralizing response.

Legend

Protein

Chemical

Disease

Primary Citation of related structures